{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2654532"],"location":["Japan"],"study_start_month":["12"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A phase II trial of oxaliplatin, capecitabine, irinotecan (XELOXIRI) and bevacizumab as first-line therapy for patients with metastatic colorectal cancer","description":"Interventions: irinotecan, oxaliplatin, capecitabine, bevacizumab\nPrimary outcome(s): Progression-free survival\nStudy Design: Single arm Non-randomized","dates":{"creation":"2014-12-15"},"accession":"2654532","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000039783"]}}